Immunocytokines Market By Disease Indication (Tumors and Cancer, Rheumatoid Arthritis), By Targeting Site (Liver, Hypothalamus, Fat muscle, B and T lymphocytes, Bone Marrow Endothelium) - Growth, Future Prospects & Competitive Analysis, 2018 – 2026
"Immunocytokines market to exhibit profitable growth during the forecast period"
The global immunocytokines market is growing significantly. In recent years monoclonal antibodies are being utilized to treat a wide array of cancer-related diseases. These monoclonal antibodies are mainly mono-specific encompassing similar immune cells which are copies of a single parent cell and are concentrated towards a definite cellular target. These antibodies due to its customizable environment, it can be used to only treat the tumor cells ineffective of the normal ones in the living body. However, a huge number of immunocytokines in the pipeline, high prevalence with no or less medical efficiency in developing nations, less awareness, the high cost of treatment, inflexible government regulations towards cancer diagnosis are factors restraining the development of immunocytokines market globally.
"Tumors and cancer segment is expected to register higher growth in the developing nations by the end of 2026"
An increasing prevalence of cancer along with along with new technological assessment in genetic sequencing and target gene selection are factors driving the overall growth of the global immunocytokines market. Few human cytokines such as IL2 have been approved (Proleukin) for diseases such as metastatic renal cell carcinoma and metastatic melanoma. Chemotherapy and drugs are used to treat cancer. Various adverse side effects that comes with the medication has made the pharmaceutical organizations to concentrate on monoclonal antibodies along with immunocytokines. According to WHO, cancer is a leading cause of mortality on a global scale, in 2018, an estimated 9.8 million individuals passed away due to cancer. Majority of them were diagnosed with lung and breast cancer.
"Lung targeting site segment is expected to register higher growth in the developing nations by the end of 2026"
Advancement in antibody-based delivery of IL2 and cytotoxics has shown promising results in recent years. As per WHO in 2018, more than 2.08 million cases were registered due to lung cancer globally. More than 11 types of immunocytokines are still in pipeline (phase I/II). They have been developed against various, tumor-associated antigens such as epithelial, cell-adhesion molecule, carbonic anhydrase 9, fibroblast activation protein, epidermal growth factor receptor, fibronectin splice variants, and, tenascin splice variants. For instance, scientists from Philogen (Italy) have developed immunocytokines based on IL2, IL12, IL4, IL10 and TNF, which are presently being inspected in pre-clinical studies. Increasing geriatric population, government or private funding for cancer research, and changing lifestyles resulting in chronic disorders are factors driving the growth of immunocytokines market.
"Increasing prevalence of cervical cancer along with advanced diagnostic procedures is gaining traction in developing economies"
North America spearheaded the market in 2017 owing to the presence of top pharmaceutical and research organizations along with increasing incidences for breast and lung cancer in the U.S., as indicated by a report published by American Cancer Society, in 2018, more than 1.6 million new cancer cases were diagnosed and around 600,000 deaths were registered. In recent years, top biotechnology and pharmaceutical companies in the U.S. and Europe have started investing in monoclonal antibodies. The driving factors include, heavy investment in R&D, approval for antibody-based molecules (more than 70), huge number of medications in pipeline and advancement in conjugated cancer therapies worldwide.
"High prevalence of cancer, less availability of medications and treatment in the developing nations"
Major players in the immunocytokines market are Alkermes Plc, AstraZeneca Plc, CytImmune, Cytune Pharma, Altor Biosciences Corporation, Apeiron Biologics AG, Paladin Labs, Teva Pharmaceutical Industries Ltd., Valor Biotherapeutics, Targa Therapeutics Corporation, Immunomedics, Inc., ImmunGene, Inc., MolMed S.p.A., Merck KGaA, Nektar Therapeutics, Pfizer, Inc., F. Hoffmann-La Roche, Ltd. and others. These companies are employing growth strategies along with new approvals for medications related to cancer.
Historical & Forecast Period
This study report represents analysis for each segment from 2016 to 2026 considering 2017 to be the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period from 2018 to 2026.
The current report also comprehends qualitative market assessment factors such as market trends, key market drivers, restraints and opportunities that gives a better market understanding of the overall immunocytokines market. Furthermore, the report also comprises graphical representation of competitive landscape based on their market initiatives and strategies, product portfolio and business strengths.
Key questions answered in this report
- What are the current market trends and dynamics in the immunocytokines market and valuable opportunities for emerging players?
- Which segment accounts for the fastest CAGR during the forecast period?
- Which end-user holds a larger market share and why?
- What is the market trend and dynamics in emerging markets such as Japan, Latin America and Middle East & Africa?
Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted
Chapter 2. Executive Summary
2.1. Global Immunocytokines Market Portraiture
2.2. Global Immunocytokines Market, By Disease Indication, 2018 (US$ Mn)
2.3. Global Immunocytokines Market, By Target Site, 2018 (US$ Mn)
2.4. Global Immunocytokines Market, by Geography, 2018 vs. 2026 (Value %)
Chapter 3. Global Immunocytokines Market: Market Dynamics and Future Outlook
3.1. Market Overview
3.2. Immunocytokines: Future Trends
3.3. Current Scenario: Prevalence for Cancer
3.4. Challenges
3.5. Opportunities
3.6. Attractive Investment Proposition, by Geography, 2018
3.7. Major Agreements, Partnerships and Collaborations
3.8. Competitive Landscape
3.8.1. Competitive Landscape, by Key Players, 2018
Chapter 4. Global Immunocytokines Market, By Disease Indication, 2016 – 2026 (US$ Mn)
4.1. Overview
4.2. Tumors and Cancer
4.3. Rheumatoid Arthritis
Chapter 5. Global Immunocytokines Market, By Target Site, 2017 (US$ Mn)
5.1. Overview
5.2. Liver
5.3. Hypothalamus
5.4. Fat muscle
5.5. B and T lymphocytes
5.6. Bone Marrow Endothelium
Chapter 6. Global Immunocytokines Market, by Geography, 2016 – 2026 (US$ Mn)
6.1. Overview
6.2. North America Immunocytokines Market Analysis, 2016 – 2026
6.2.1. North America Immunocytokines Market, By Disease Indication, 2016 – 2026 (US$ Mn)
6.2.2. North America Immunocytokines Market, By Target Site, 2016 – 2026 (US$ Mn)
6.2.3. North America Immunocytokines Market, by Country, 2016 – 2026 (US$ Mn)
6.2.3.1. U.S.
6.2.3.2. Canada
6.3. Europe Immunocytokines Market Analysis, 2016 – 2026
6.3.1. Europe Immunocytokines Market, By Disease Indication, 2016 – 2026 (US$ Mn)
6.3.2. Europe Immunocytokines Market, By Target Site, 2016 – 2026 (US$ Mn)
6.3.3. Europe Immunocytokines Market, by Country, 2016 – 2026 (US$ Mn)
6.3.3.1. U.K.
6.3.3.2. Germany
6.3.3.3. Rest of Europe
6.4. Asia Pacific Immunocytokines Market Analysis, 2016 – 2026
6.4.1. Asia Pacific Immunocytokines Market, By Disease Indication, 2016 – 2026 (US$ Mn)
6.4.2. Asia Pacific Immunocytokines Market, By Target Site, 2016 – 2026 (US$ Mn)
6.4.3. Asia Pacific Immunocytokines Market, by Country, 2016 – 2026 (US$ Mn)
6.4.3.1. Japan
6.4.3.2. China
6.4.3.3. Rest of APAC
6.5. Latin America Immunocytokines Market Analysis, 2016 – 2026
6.5.1. Latin America Immunocytokines Market, By Disease Indication, 2016 – 2026 (US$ Mn)
6.5.2. Latin America Immunocytokines Market, By Target Site, 2016 – 2026 (US$ Mn)
6.5.3. Latin America Immunocytokines Market, by Country, 2016 – 2026 (US$ Mn)
6.5.3.1. Brazil
6.5.3.2. Mexico
6.5.3.3. Rest of Latin America
6.6. Middle East & Africa (MEA) Immunocytokines Market Analysis, 2016 – 2026
6.6.1. MEA Immunocytokines Market, By Disease Indication, 2016 – 2026 (US$ Mn)
6.6.2. MEA Immunocytokines Market, By Target Site, 2016 – 2026 (US$ Mn)
6.6.3. MEA Immunocytokines Market, by Region, 2016 – 2026 (US$ Mn)
6.6.3.1. GCC
6.6.3.2. Rest of MEA
Chapter 7. Company Profiles
7.1. AstraZeneca Plc
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. Key Developments
7.2. Alkermes Plc
7.3. CytImmune
7.4. Cytune Pharma
7.5. Altor Biosciences Corporation
7.6. Apeiron Biologics AG
7.7. Paladin Labs
7.8. Teva Pharmaceutical Industries Ltd.
7.9. Valor Biotherapeutics
7.10. Targa Therapeutics Corporation
7.11. Immunomedics, Inc.
7.12. ImmunGene, Inc.
7.13. MolMed S.p.A.
7.14. Merck KGaA
7.15. Nektar Therapeutics
7.16. Pfizer, Inc.
7.17. F. Hoffmann-La Roche, Ltd.
TABLE 1 Market Snapshot: Global Immunocytokines Market
TABLE 2 Global Immunocytokines Market, By Disease Indication, 2016–2026 (US$ Mn)
TABLE 3 Global Immunocytokines Market, by Geography, 2016–2026 (US$ Mn)
TABLE 4 North America Immunocytokines Market, By Disease Indication, 2016–2026 (US$ Mn)
TABLE 5 North America Immunocytokines Market, By Target Site, 2016–2026 (US$ Mn)
TABLE 6 North America Immunocytokines Market, by Country, 2016–2026 (US$ Mn)
TABLE 7 Europe Immunocytokines Market, By Disease Indication, 2016–2026 (US$ Mn)
TABLE 8 Europe Immunocytokines Market, By Target Site, 2016–2026 (US$ Mn)
TABLE 9 Europe Immunocytokines Market, by Country/Region, 2016–2026 (US$ Mn)
TABLE 10 Latin America Immunocytokines Market, By Disease Indication, 2016–2026 (US$ Mn)
TABLE 11 Latin America Immunocytokines Market, By Target Site, 2016–2026 (US$ Mn)
TABLE 12 Latin America Immunocytokines Market, by Country/Region, 2016–2026 (US$ Mn)
TABLE 13 Asia Pacific Immunocytokines Market, By Disease Indication, 2016–2026 (US$ Mn)
TABLE 14 Asia Pacific Immunocytokines Market, By Target Site, 2016–2026 (US$ Mn)
TABLE 15 Asia Pacific Immunocytokines Market, By Disease Indication, 2016–2026 (US$ Mn)
TABLE 16 Asia Pacific Immunocytokines Market, by Country/Region, 2016–2026 (US$ Mn)
TABLE 17 Middle East & Africa Immunocytokines Market, By Disease Indication, 2016–2026 (US$ Mn)
TABLE 18 Middle East & Africa Immunocytokines Market, By Target Site, 2016–2026 (US$ Mn)
TABLE 19 Middle East & Africa Immunocytokines Market, by Region, 2016–2026 (US$ Mn)
TABLE 20 Alkermes Plc.: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 21 AstraZeneca Plc: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 22 Cytune Pharma: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 23 CytImmune: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 24 Altor Biosciences Corporation: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 25 Apeiron Biologics AG: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 26 Paladin Labs.: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 27 Teva Pharmaceutical Industries Ltd.: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 28 Valor Biotherapeutics: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 29 Targa Therapeutics Corporation: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 30 Immunomedics, Inc.: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 31 ImmunGene, Inc.: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 32 MolMed S.p.A.: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 33 Merck KGaA: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 34 Nektar Therapeutics: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 35 Pfizer, Inc.: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 36 F. Hoffmann-La Roche, Ltd.: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
FIG. 1 Global Immunocytokines Market: Research Methodology
FIG. 2 Market Size Estimation – Top Down & Bottom up Approach
FIG. 3 Global Immunocytokines Market Segmentation
FIG. 4 Global Immunocytokines Market, By Disease Indication, 2017 (US$ Mn)
FIG. 5 Global Immunocytokines Market, By Target Site, 2017 (US$ Mn)
FIG. 6 Global Immunocytokines Market, by Geography, 2017 (US$ Mn)
FIG. 7 Attractive Investment Proposition, by Geography, 2017
FIG. 8 Global Market Positioning of Key Immunocytokines Manufacturers, 2017
FIG. 9 Global Immunocytokines Market for Tumors and Cancer, 2016–2026 (US$ Mn)
FIG. 10 Globla Immunocytoines Market for Rheumatoid Arthritis, 2016–2026 (US$ Mn)
FIG. 11 Global Immunocytokines Market for Liver, 2016–2026 (US$ Mn)
FIG. 12 Global Immunocytokines Market for Hypothalamus, 2016–2026 (US$ Mn)
FIG. 13 Global Immunocytokines Market for Fat muscle, 2016–2026 (US$ Mn)
FIG. 14 Global Immunocytokines Market for B and T lymphocytes, 2016–2026 (US$ Mn)
FIG. 15 Global Immunocytokines Market for Bone Marrow Endothelium, 2016–2026 (US$ Mn)
FIG. 16 U.S. Immunocytokines Market, 2016–2026 (US$ Mn)
FIG. 17 Canada Immunocytokines Market, 2016–2026 (US$ Mn)
FIG. 18 U.K. Immunocytokines Market, 2016–2026 (US$ Mn)
FIG. 19 Germany Immunocytokines Market, 2016–2026 (US$ Mn)
FIG. 20 Rest of Europe Immunocytokines Market, 2016–2026 (US$ Mn)
FIG. 21 Japan Immunocytokines Market, 2016–2026 (US$ Mn)
FIG. 22 China Immunocytokines Market, 2016–2026 (US$ Mn)
FIG. 23 Rest of Asia Pacific Immunocytokines Market, 2016–2026 (US$ Mn)
FIG. 24 Brazil Immunocytokines Market, 2016–2026 (US$ Mn)
FIG. 25 Mexico Immunocytokines Market, 2016–2026 (US$ Mn)
FIG. 26 Rest of Latin America Immunocytokines Market, 2016–2026 (US$ Mn)
FIG. 27 GCC Immunocytokines Market, 2016–2026 (US$ Mn)
FIG. 28 Rest of Middle East & Africa Immunocytokines Market, 2016–2026 (US$ Mn)
Choose License
Contact Information
: sales@briskinsights.com
: +448081890034 (UK)